Navigation Links
Omnitura Therapeutics Announces Private Placement Financing
Date:1/29/2009

Company will proceed with clinical trials of first-in-class multivalent therapies for cancer

REDWOOD SHORES, Calif., Jan. 29 /PRNewswire/ -- Omnitura Therapeutics Inc. ("Omnitura") announced today that it has entered into a $24 million private placement agreement with multiple closings. Under the terms of this financing, investments will be made in three tranches: $8 million before March 31, 2009, $8 million before December 31, 2009 and $8 million before December 31, 2010. "We anticipate that these funds will cover Omnitura's operations for three years and enable us to proceed with Phase I and Phase II clinical development of Aneustat(TM), our lead multivalent cancer therapy," said Jeff Dao, President & COO of Omnitura. "In addition to our clinical development program, these funds will also enable us to further cultivate strategic alliances and implement the next steps of our comprehensive financing plans," said Mr. Dao.

Aneustat(TM) represents a first-in-class multifunctional multitargeted (MFMT(TM)) therapy, specifically designed to address the heterogeneous nature of cancer. Omnitura has exclusive worldwide rights to Aneustat(TM) under a license agreement with Genyous Biomed International, Inc.

About Omnitura Therapeutics Inc. and MFMT(TM) Therapies

Omnitura Therapeutics Inc., www.omnitura.com founded in 2001, is a bio-pharmaceutical company that develops and facilitates the marketing of a new class of multivalent drugs for the treatment of cancer. Our mission is to commercialize Multifunctional Multitargeted ("MFMT(TM)") oncology drugs. MFMT(TM) drugs possess multiple therapeutic functions and act upon multiple biological targets to treat complex chronic diseases, including cancer.

Omnitura's MFMT(TM) drug candidates, acquired via an exclusive worldwide license and joint development arrangement with Genyous Biomed International Inc., were designed using a systems biology strategy that takes into consideration crosstalk between cancer cells, their microenvironment and the host organism (e.g. the immune system response). The comprehensive therapeutic activity profile of MFMT(TM) drugs represents an opportunity to significantly improve outcomes. By possessing multiple therapeutic functions and working through a multiplicity of biological targets, relatively low and well-tolerated doses of therapeutic actives are sufficient to treat cancer while minimizing disruption of and restoring the body's homeostasis. This unique characteristic of MFMT(TM) drug candidates leads to less risk of toxicity, side effects and the development of drug resistance.


'/>"/>
SOURCE Omnitura Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one ... of their brand, UP4™ Probiotics, into Target stores nationwide. The company, which has ... add Target to its list of well-respected retailers. This list includes such fine ...
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
Breaking Biology Technology:
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
Breaking Biology News(10 mins):